Earnings Call · Q1 FY2022·2022-05-12

Q1 22EPS -1.47%·Rev n/aQ4 21EPS +24.05%·Rev n/aQ3 21EPS -1.54%·Rev n/aQ2 21EPS +86.70%·Rev n/a⚠ consensus missing

Eledon Pharmaceuticals, Inc. ELDN

Paul Little — Investor Relations or Corporate Communications

David-Alexandre Gros — Chief Executive Officer

Steve Perrin — President and Chief Scientific Officer

+10.0%1d on move date+7.6% vs SPY3d+22.4%5d+29.4%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ELDN calls or request research access.

More ELDN calls Browse calls Request research access